Questions about COVID-19?

What Patients & Families Need to Know | New Visitor Policy | Guidance for Community Healthcare Providers

A photo of William Seibel.

Member, Division of Oncology

Assistant Professor, UC Department of Pediatrics

513-803-4870

513-636-3549

Biography & Affiliation

Biography

William Seibel, PhD, completed his doctorate in chemistry at Harvard University. He then worked for 19 years in various positions at Procter & Gamble Pharmaceuticals, managing migraine and antimicrobials drug discovery groups as well as technology groups in computational, modeling, structural biology and combinatorial chemistry. He then served as head of the University of Cincinnati College of Medicine’s Compound Library and Cheminformatics group and as project manager for the Drug Discovery Center, both of which continue through his Cincinnati Children's Hospital Medical Center appointment. His interests are in working with various collaborators to find the most efficient and effective approaches to identify biologically active small molecules, and advance these leads to clinical candidate status.

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Departments

Oncology, Cancer and Blood Diseases

Education

PhD: Harvard University, Cambridge, MA, 1987.

Publications

Diverse Chemical Scaffolds Enhance Oligodendrocyte Formation by Inhibiting CYP51, TM7SF2, or EBP. Allimuthu, D; Hubler, Z; Najm, FJ; Tang, H; Bederman, I; Seibel, W; Tesar, PJ; Adams, DJ. Cell Chemical Biology. 2019; 26:593-599.e4.

Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Allaway, RJ; Wood, MD; Downey, SL; Bouley, SJ; Traphagen, NA; Wells, JD; Batra, J; Melancon, SN; Ringelberg, C; Seibel, W; et al. Oncotarget. 2018; 9:15860-15875.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Jiang, X; Hu, C; Ferchen, K; Nie, J; Cui, X; Chen, C; Cheng, L; Zuo, Z; Seibel, W; He, C; et al. Nature Communications. 2017; 8.

Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H+)-ATPase Inhibitors. Patil, R; Kulshrestha, A; Tikoo, A; Fleetwood, S; Katara, G; Kolli, B; Seibel, W; Gilman-Sachs, A; Patil, SA; Beaman, KD. Molecules. 2017; 22:1559-1559.

A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression. James, MA; Seibel, WL; Kupert, E; Hu, XX; Potharla, VY; Anderson, MW. Anti-Cancer Drugs: international journal on anti-cancer agents. 2015; 26:518-530.

Combined Rational Design and a High Throughput Screening Platform for Identifying Chemical Inhibitors of a Ras-activating Enzyme. Evelyn, CR; Biesiada, J; Duan, X; Tang, H; Shang, X; Papoian, R; Seibel, WL; Nelson, S; Meller, J; Zheng, Y. The Journal of biological chemistry. 2015; 290:12879-12898.

A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation. Chen, Y; Tang, H; Seibel, W; Papoian, R; Li, X; Lambert, NA; Palczewski, K. Investigative Ophthalmology and Visual Science. 2015; 56:2553-2567.

Identification of Imidazoquinoline Derivatives as Potent Antiglioma Agents. Patil, SA; Pfeffer, SR; Seibel, WL; Pfeffer, LM; Miller, DD. Medicinal chemistry (Shariqah (United Arab Emirates)). 2015; 11:400-406.

Target validation and structure-activity analysis of a series of novel PCNA inhibitors. Dillehay, KL; Seibel, WL; Zhao, D; Lu, S; Dong, Z. Pharmacology Research and Perspectives. 2015; 3:e00115-e00115.

Expansion of First-in-Class Drug Candidates That Sequester Toxic All-Trans-Retinal and Prevent Light-Induced Retinal Degeneration. Zhang, J; Dong, Z; Mundla, SR; Hu, XE; Seibel, W; Papoian, R; Palczewski, K; Golczak, M. Molecular Pharmacology. 2015; 87:477-491.